An observational study in Muscle Spasticity, sponsored by Allergan. Completed at 55 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-11.
Sponsored by Allergan · Observational
This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
704 studies on the registry are indexed under Muscle Spasticity; 149 are open to participants now.
This study's enrollment of 744 is above the median of 60 across 162 observational studies indexed under Muscle Spasticity.
Browse Muscle Spasticity studies →Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Muscle Spasticity
Exclusion Criteria:
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Drug: onabotulinumtoxinA
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Also known as: BOTOX®, botulinum toxin Type A
Percentage of Patients Reporting Satisfaction with Treatment
Time frame: 5 Weeks
Percentage of Health Care Providers Reporting Satisfaction with Treatment
Time frame: 12 Weeks
Physical Functioning on a 5-Point Scale
Time frame: 5 Weeks
Severity of Pain on an 11-Point Scale
Time frame: 5 Weeks
Disability Assessment on a 4-Point Scale
Time frame: 12 Weeks
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan